FY2025 · ended Dec 31, 2025 · Revenue $958.40M, +432.1% YoY · Filed Feb 19, 2026
Madrigal Pharmaceuticals, Inc. (MDGL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $958.4 million and a net loss of $288.3 million. Free cash flow was -$190.0 million. As of Sep 30, 2026 it held $961.0 million in cash and investments and $354.2 million in total debt.
Revenue (TTM)
$1.43B
+92.8% vs year-ago TTM
Net income (TTM)
$-155.46M
+46.2% vs year-ago TTM
Operating cash flow (TTM)
$-157.01M
+2.2% vs year-ago TTM
Free cash flow (TTM)
$-168.65M
-4.3% vs year-ago TTM
EPS (TTM)
$-5.35
+40.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
22.94M
+3.9% vs prior year
Net cash
$606.75M
as of Sep 30, 2026
Operating margin
-10.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDGL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Conshohocken, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1157601
- Former names
- MADRIGAL PHARMACEUTICALS, INC. (until Nov 3, 2026); SYNTA PHARMACEUTICALS CORP (until Aug 1, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 |
| Operating income | -$300.1M | -$497.9M | -$380.5M | -$293.6M | -$242.5M |
| Net income | -$288.3M | -$465.9M | -$373.6M | -$295.4M | -$241.8M |
| Diluted EPS | -$12.85 | -$21.90 | -$19.99 | -$17.23 | — |
| Operating cash flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M | -$183.9M |
| Free cash flow | -$190.0M | -$457.0M | -$325.7M | -$225.1M | -$184.1M |
| Total assets | $1.3B | $1.0B | $640.5M | $362.6M | $273.3M |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M |
| Stockholders' equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M |
| Cash and investments | $983.6M | $926.3M | $634.1M | $358.8M | $270.3M |
| Total debt | $347.6M | $119.6M | $117.2M | $70.3M | $797,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 12, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 16, 2026 |
All 1001 Madrigal Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.